View Author
scopus: 7005410978

Kamali, F.

(Farhad Kamali)


patient coumarin study anticoagulation warfarin dosing therapy anticoagulant trial stroke atrial fibrillation –effectivenes cyp 2c coumarin derivatives treatment range cost –effectiveness fibrillation atrial country monitoring university percentage time group pharmacogenetic vkorc anticoagulant therapy netherland health algorithm genotyping acenocoumarol science derivative eu-pact future event anticoagulant care european countries phenprocoumon utrecht european clinic target measurement percentage review 100  patient-years austria management pharmacogenomic complication requirement eu-pact trial information difference cost –effectiveness analyses sweden hospital randomized target inr range month germany outcome quality genotype-guided schie dabigatran 100  loading polymorphism target range inr measurement method dose requirements inr measurements anticoagulation therapy patient-year effectiveness greece




2 Most Recent Publications

Cost-effectiveness of pharmacogenetics in anticoagulation: International differences in healthcare systems and costs (Article)
Verhoef, T.I. Orlewska, E. Manolopoulos, V.G. Pirmohamed, M. Siebert, U. Stingl, J.C. Wadelius, M. Boer, A. de Maitland-van der Zee, A-H. Schie, R.M.F. van Bayat, S. Daly, A.K. Geitona, M. Haschke-Becher, E. Hughes. D.A. Kamali, F. Levin, L.A.
2012-09-01
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design (Article)
Schie, R.M.F. van Wadelius, M. Briz, M. Rosendaal, F.R. Redekop, W.K. Pirmohamed, M. Maitland-van der Zee, A-H. Kamali, F. Daly, A.K. Manolopoulos, V.G. Boer, A. de Barallon, R. Verhoef, T.I. Kirchheiner, J. Haschke-Becher, E.
2009-10-01